Companies founded on innovation and strong science

RougeTx is a spin-off from Leiden University Medical Center (LUMC) and is developing first-inclass small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction.

Pericytes regulate angiogenesis and support blood vessel integrity and function.

The aim is to move beyond current symptom management toward urgently needed diseasemodifying treatments for vascular diseases.

The lead program targets Hereditary Hemorrhagic Telangiectasia (HHT) along with additional indications related to vascular stability diseases.

P53 Invest participated in a series A round lead by BioGeneration Ventures (BGV), Angelini Ventures, and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocaptial Partners, ROM Utrecht Region and Kerna Ventures.

Serenatis Bio is developing a pipeline of novel small-molecule drugs with unique mechanisms of action to transform the treatment landscape for obsessive-compulsive disorder (OCD), a debilitating mental illness affecting millions worldwide.

Current treatments remain outdated with slow-acting medications and limited access to cognitive behavioral therapy plagued by high dropout rates. As a result, millions continue to struggle despite existing treatment options. By tailoring treatments to the neurobiological profiles underlying the mechanisms and root neurological causes of OCD, the company aims to develop treatments that work faster and more effectively while minimising side effects.

The proprietary platform allows the company to generate libraries of bispecific antibody-drug conjugates, multivalent multispecifics, or any combination thereof.

From a vast, untapped space of potential components and target combinations, the platform can rapidly identify the most potent drug candidates through iterative screening and design—leveraging its 1-day design process. With this, the company can create and find drugs that won’t otherwise be identified—unlocking the next generation of multifunctional antibody therapeutics.

Our portfolio company, Arxx Therapeutics, merged with Oxitope Pharma in 2024 to form Calluna Pharma, a clinical stage company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases by leveraging the body’s innate immune system.

The Company’s therapeutic approach targets upstream amplifiers of disease, offering potential applicability across a diverse array of medical conditions. Calluna has a robust pipeline of selective antibodies targeting immunological diseases with enhanced efficacy, including several first-in-class clinical candidates.

The Company is based in Oslo, Norway, with Forbion, p53, Sarsia and Investinor as lead investors.  

Teitur develops novel therapeutics for treating or preventing neurodegenerative diseases. The company’s ambition and commitment is to create new treatments for patients suffering from neurodegenerative diseases to help them live a longer, better and happier life.

From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders.

More than 200 million patients suffer from neurodegenerative disorders world-wide. Today, no treatments are available to prevent the relentless progression of neurodegeneration, affecting memory, movement, and quality of life for them and their loved ones.

Teitur is dedicated to developing novel compounds that can address this unmet medical need and provide true disease modifying opportunities to improve the lives of patients. P53 Invest participated in a series A round lead by Sunstone Life Science Ventures and Sound Bioventures, together with Industrifonden and Innovestor’s Life Science Fund

Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.

It addressed the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

The company aims to transform the treatment and redefine how the world approaches, prevents, and heals mental health disorders.

specialist scientific advisory network, provide guidance on bringing transformative ideas into the clinic. The Centenara Labs subsidiary companies share lab space, equipment, and offices, with plug-and-play access to a state-of-the-art research infrastructure.

It addressed the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

The company aims to transform the treatment and redefine how the world approaches, prevents, and heals mental health disorders.

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for cancer, infectious diseases, and autoimmune conditions.

The company is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. By intelligent design, Nykode’s platform can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Nykode Therapeutics technology platform has the potential to address many diseases with a high unmet medical need.